Dupixent Dosing Recommendations
For atopic dermatitis in adults, initiate Dupixent with 600 mg (two 300 mg injections) followed by 300 mg every 2 weeks; for asthma and chronic rhinosinusitis with nasal polyps in adults, use 300 mg every 2 weeks (with or without loading dose depending on comorbidities); pediatric dosing is weight-based and varies by indication. 1
Atopic Dermatitis Dosing
Adults
- Loading dose: 600 mg (two 300 mg injections)
- Maintenance: 300 mg every 2 weeks (Q2W) 1
Pediatric Patients (6 months to 5 years)
Weight-based dosing without loading dose:
- 5 to <15 kg: 200 mg every 4 weeks (Q4W)
- 15 to <30 kg: 300 mg every 4 weeks (Q4W) 1
Pediatric Patients (6 to 17 years)
Weight-based with loading dose:
- 15 to <30 kg: 600 mg loading (two 300 mg injections), then 300 mg Q4W
- 30 to <60 kg: 400 mg loading (two 200 mg injections), then 200 mg Q2W
- ≥60 kg: 600 mg loading (two 300 mg injections), then 300 mg Q2W 1
The 2024 AAD guidelines strongly favor dupilumab as first-line systemic therapy for moderate-to-severe atopic dermatitis, with all surveyed guideline workgroup members selecting it as their preferred agent 2. This reflects its superior safety profile and high-certainty efficacy evidence from large RCTs including 52-week trials 2.
Asthma Dosing
Adults and Pediatric Patients ≥12 years
Standard dosing:
- Loading: 400 mg (two 200 mg injections) OR 600 mg (two 300 mg injections)
- Maintenance: 200 mg Q2W OR 300 mg Q2W 1
For specific populations requiring higher dosing (600 mg loading/300 mg Q2W):
- Oral corticosteroid-dependent asthma
- Comorbid moderate-to-severe atopic dermatitis
- Adults with comorbid chronic rhinosinusitis with nasal polyps 1
Pediatric Patients (6 to 11 years)
- 15 to <30 kg: 300 mg Q4W
- ≥30 kg: 200 mg Q2W 1
Important caveat: For children 6-11 years with asthma AND comorbid moderate-to-severe atopic dermatitis, follow the atopic dermatitis dosing table which includes a loading dose 1.
Chronic Rhinosinusitis with Nasal Polyps
Adults and Pediatric Patients ≥12 years
- No loading dose
- Maintenance: 300 mg Q2W 1
The 2023 Joint Task Force guidelines conditionally recommend biologics for CRSwNP, with dupilumab and omalizumab showing the most benefit across patient-important outcomes 3. Network meta-analysis data suggest dupilumab (600 mg loading/300 mg Q2W) ranks highest for quality of life improvement and olfactory function restoration 4.
Eosinophilic Esophagitis
Adults and Pediatric Patients ≥1 year (≥15 kg)
Weight-based without loading dose:
- 15 to <30 kg: 200 mg Q2W
- 30 to <40 kg: 300 mg Q2W
- ≥40 kg: 300 mg every week (QW) 1
Prurigo Nodularis (Adults only)
- Loading dose: 600 mg (two 300 mg injections)
- Maintenance: 300 mg Q2W 1
Chronic Obstructive Pulmonary Disease (Adults only)
- No loading dose
- Maintenance: 300 mg Q2W 1
Key Clinical Considerations
Dosing interval extension: While FDA-approved dosing is Q2W for most indications, emerging real-world evidence suggests that after achieving disease control (typically 6-12 months), some patients with CRSwNP may maintain stability with extended intervals (Q4W or longer) 5. However, this is off-label and should only be considered after documented sustained control on standard dosing. For atopic dermatitis, trial data demonstrate that extending beyond Q2W results in dose-dependent worsening of response 6.
Comorbidity considerations: Patients with multiple type 2 inflammatory conditions are extremely common (92% of asthma patients in the RAPID registry had ≥1 coexisting type 2 disease) 7. When multiple indications exist, use the higher dosing regimen—typically the atopic dermatitis dosing with loading dose 1.
Pediatric dosing pitfalls: The availability of two concentrations (200 mg/1.14 mL and 300 mg/2 mL) creates safety concerns 8. Always verify weight-based dosing carefully, particularly in the 6-11 year age group where dosing varies significantly by weight and indication.